Technology | June 29, 2006

FDA Approves Heart Stent Study

The FDA granted Conor Medsystems Inc. full approval to enroll up to 1,700 patients in its heart stent clinical trial.
The study will test Conor’s CoStar heart stent coated with the cancer drug paclitaxel at 85 clinical sites to see if it reduces incidents of major adverse cardiac events such as heart attacks, compared with Boston Scientific Corp.’s Taxus Express2 stent, which is also coated with paclitaxel.
Stents are tiny wire mesh tubes that are expanded inside plaque-congested heart arteries with a balloon to act as scaffolding to keep the blood vessel open. Best-selling stents are coated with drugs to help prevent the artery from reclogging by keeping tissue from growing through the mesh. Conor claims the CoStar is different from other drug-coated stents, in that it uses tiny reservoirs built into the stent to release the drug.
However, Conor and Canadian specialty drug maker Angiotech Pharmaceuticals Inc. are in legal battles in several countries over Angiotech’s patents for using paclitaxel to coat stents. Angiotech licenses and supplies the drug to Boston Scientific to coat the Taxus Express2 stent.

Related Content

The Abbott Vascular Xience Sierra drug eluting stent (DES). The XIENCE 28 and XIENCE 90 studies presented at TCT 2020 showed the stent can be used safely with only one month of dual antiplatelet therapy (DAPT). #TCT #TCTconnect #TCT2020
News | Stents Drug Eluting | October 16, 2020
October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatele
Resolute Onyx Drug-Eluting Stent Noninferior to Polymer-Free Drug-Coated Stent With One-Month DAPT
News | Stents Drug Eluting | September 30, 2019
The first randomized trial to compare a durable polymer drug- eluting stent to a polymer-free drug-coated stent in...
Biodegradable Polymer Stent Plus Shortened DAPT Safe and Effective in Unprotected Left Main CAD
News | Stents Drug Eluting | September 30, 2019
A biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT)...
Superiority of Orsiro Over Xience Demonstrated in STEMI Patients
News | Stents Drug Eluting | September 05, 2019
Biotronik's ultrathin Orsiro stent demonstrated superiority over Xience with respect to target lesion failure (TLF) at...
Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...